These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 9688185)

  • 1. Expression of the cell-cycle-related proteins E2F-1, p53, mdm-2, p21waf-1, and Ki-67 in multiple myeloma: correlation with cyclin-D1 immunoreactivity.
    Lai R; Medeiros LJ; Wilson CS; Sun NC; Koo C; McCourty A; Brynes RK
    Mod Pathol; 1998 Jul; 11(7):642-7. PubMed ID: 9688185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulated ectopic expression of cyclin D1 induces transcriptional activation of the cdk inhibitor p21 gene without altering cell cycle progression.
    Hiyama H; Iavarone A; LaBaer J; Reeves SA
    Oncogene; 1997 May; 14(21):2533-42. PubMed ID: 9191053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell cycle regulators in multiple myeloma: prognostic implications of p53 nuclear accumulation.
    Pruneri G; Carboni N; Baldini L; Intini D; Colombi M; Bertolini F; Valentini S; Maisonneuve P; Viale G; Neri A
    Hum Pathol; 2003 Jan; 34(1):41-7. PubMed ID: 12605365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Down-regulation of cyclin A gene expression upon genotoxic stress correlates with reduced binding of free E2F to the promoter.
    Spitkovsky D; Schulze A; Boye B; Jansen-Dürr P
    Cell Growth Differ; 1997 Jun; 8(6):699-710. PubMed ID: 9186003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological features.
    Ioachim E
    Int J Clin Pract; 2008 Nov; 62(11):1736-43. PubMed ID: 19143860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclin D1 and E2F-1 immunoreactivity in bone marrow biopsy specimens of multiple myeloma: relationship to proliferative activity, cytogenetic abnormalities and DNA ploidy.
    Wilson CS; Butch AW; Lai R; Medeiros LJ; Sawyer JR; Barlogie B; McCourty A; Kelly K; Brynes RK
    Br J Haematol; 2001 Mar; 112(3):776-82. PubMed ID: 11260083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiparameter immunohistochemical analysis of the cell cycle proteins cyclin D1, Ki-67, p21WAF1, p27KIP1, and p53 in mantle cell lymphoma.
    Izban KF; Alkan S; Singleton TP; Hsi ED
    Arch Pathol Lab Med; 2000 Oct; 124(10):1457-62. PubMed ID: 11035575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. K-ras modulates the cell cycle via both positive and negative regulatory pathways.
    Fan J; Bertino JR
    Oncogene; 1997 May; 14(21):2595-607. PubMed ID: 9191059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of the E2F transcription factor by cyclin D1 is blocked by p16INK4, the product of the putative tumor suppressor gene MTS1.
    Schulze A; Zerfass K; Spitkovsky D; Henglein B; Jansen-Dürr P
    Oncogene; 1994 Dec; 9(12):3475-82. PubMed ID: 7970707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of E2F-1 gene expression by p130 (Rb2) and D-type cyclin kinase activity.
    Johnson DG
    Oncogene; 1995 Nov; 11(9):1685-92. PubMed ID: 7478595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional interplay between p53 and E2F through co-activator p300.
    Lee CW; Sørensen TS; Shikama N; La Thangue NB
    Oncogene; 1998 May; 16(21):2695-710. PubMed ID: 9652736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered expression and molecular abnormalities of cell-cycle-regulatory proteins in rhabdomyosarcoma.
    Takahashi Y; Oda Y; Kawaguchi K; Tamiya S; Yamamoto H; Suita S; Tsuneyoshi M
    Mod Pathol; 2004 Jun; 17(6):660-9. PubMed ID: 15098008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical expression of the p53, mdm2, p21/Waf-1, Rb, p16, Ki67, cyclin D1, cyclin A and cyclin B1 proteins and apoptotic index in T-cell lymphomas.
    Kanavaros P; Bai M; Stefanaki K; Poussias G; Rontogianni D; Zioga E; Gorgoulis V; Agnantis NJ
    Histol Histopathol; 2001 Apr; 16(2):377-86. PubMed ID: 11332692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mdm2 inhibition of p53 induces E2F1 transactivation via p21.
    Wunderlich M; Berberich SJ
    Oncogene; 2002 Jun; 21(28):4414-21. PubMed ID: 12080472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical expression of cyclin D1, E2F-1, and Ki-67 in benign and malignant thyroid lesions.
    Saiz AD; Olvera M; Rezk S; Florentine BA; McCourty A; Brynes RK
    J Pathol; 2002 Oct; 198(2):157-62. PubMed ID: 12237874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roles of E2F1 in mesangial cell proliferation in vitro.
    Inoshita S; Terada Y; Nakashima O; Kuwahara M; Sasaki S; Marumo F
    Kidney Int; 1999 Dec; 56(6):2085-95. PubMed ID: 10594784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of D-type cyclins, E2F-1, SV40 large T antigen and HPV16 E7 rescue cell cycle arrest of tsBN462 cells caused by the CCG1/TAF(II)250 mutation.
    Sekiguchi T; Nishimoto T; Hunter T
    Oncogene; 1999 Mar; 18(10):1797-806. PubMed ID: 10086334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct interaction of p21 cyclin-dependent kinase inhibitor with the retinoblastoma tumor suppressor protein.
    Nakanishi M; Kaneko Y; Matsushime H; Ikeda K
    Biochem Biophys Res Commun; 1999 Sep; 263(1):35-40. PubMed ID: 10486249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TP53 alterations in relation to the cell cycle-associated proteins p21, cyclin D1, CDK4, RB, MDM2, and EGFR in cancers of the uterine corpus.
    Skomedal H; Kristensen GB; Nesland JM; Børresen-Dale AL; Tropé C; Holm R
    J Pathol; 1999 Apr; 187(5):556-62. PubMed ID: 10398121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequent disruption of the RB1 pathway in diffuse large B cell lymphoma: prognostic significance of E2F-1 and p16INK4A.
    Møller MB; Kania PW; Ino Y; Gerdes AM; Nielsen O; Louis DN; Skjødt K; Pedersen NT
    Leukemia; 2000 May; 14(5):898-904. PubMed ID: 10803523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.